01 Oct New HPV Vaccine Has Potential To Prevent Nearly All Cervical Pre-Cancers
Medical Research: What are the main findings of the study?
Dr. Joura: The upcoming ninevalent vaccine has the potential to prevent 85% of the cervical precancers and surgeries such as LEEP (conization)
Medical Research: What was most surprising about the results?
Dr. Joura: In coinfections we got the same result with various mathematical models: high grade disease will be effectively prevented, since these 9 types are the most prevalent strains, in single AND in co-infections
Medical Research: What should clinicians and patients take away from your report?
Dr. Joura: With the currently available vaccines we achieve an excellent protection, but this level of protection will be even better in the future. The key thing is that the coverage for HPV vaccination has to improve in the future.
Medical Research: What recommendations do you have for future research as a result of this study?
Dr. Joura: After this modeling and the randomized phase III trials, we need results in a real life situation and long term follow up. this research has to be extended to other HPV related diseases, other age groups and males.
Elmar A. Joura, Kevin A. Ault, F. Xavier Bosch, Darron Brown, Jack Cuzick, Daron Ferris, Suzanne M. Garland, Anna R. Giuliano, Mauricio Hernandez-Avila, Warner Huh, Ole-Erik Iversen, Susanne K. Kjaer, Joaquin Luna, Dianne Miller, Joseph Monsonego, Nubia Munoz, Evan Myers, Jorma Paavonen, Punnee Pitisuttithum, Marc Steben, Cosette M. Wheeler, Gonzalo Perez, Alfred Saah, Alain Luxembourg, Heather L. Sings, and Christine Velicer